Exhibitors & SponsorsBecome an Exhibitor or Sponsor
Bristol-Myers Squibb Access Support
Our mission is unchanged as we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation, and passion for improving the lives of patients. This singular focus drives our aspiration to discover, develop, and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.
We’ve built a portfolio of paradigm-changing therapies and a leading oncology pipeline. While we’ve made great strides in our fight against cancer, we are determined to do more—to work harder and to reach higher. We will do this with the same passion, agility, and entrepreneurial spirit that has sustained the heart of our culture and has made us the leader in oncology that we are today.
We know that our mission is not a quick or easy one, but we are up to the task: we aspire to cure cancer.
Radiaderm, R1 and R2 system represents a useful addition to the physician’s and nurse navigator’s armamentarium in preventing and treating the symptoms of acute radiation dermatitis and other oncology complications. There is an increasing body of published evidence and clinical experience to support the use of the R1 and R2.
The majority of currently used treatments are inadequate in terms of efficacy and safety/tolerability and there is clinical evidence to support their use is limited.
Water-Jel Technologies has an ongoing program of advanced research and development that caters to the emerging requirements of first-response burn injury & oncology concerns. All products are manufactured in the U.S. in our FDA-regulated and ISO-certified facility.